As advised via PHARMAC tender of 29 June 2018 there is to be a change in the listing and future sole supply.

New listing from 1 January 2018

Desferrioxamine mesilate DBL Inj 500 mg  10 vial   Pharmacode 461598 Schedule price $84.53

Incumbent brand

Desferal Inj 500 mg  10 vial                                            Pharmacode 261769 Schedule price $51.52

Reference pricing will not apply. HML (Hospital Supply Status) will be implemented 1 March 2019 and CSS (Community Supply Status) 1 June 2019.

As of the date of this notification ProPharma / PWR cannot accept Desferal Inj 500 mg for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author